Mike Garrett, Flamingo

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its sights

As the biggest name in an­ti­sense tech­nol­o­gy, Io­n­is has long fo­cused on test­ing the in­ter­play be­tween oligonu­cleotides and RNA for ther­a­peu­tic ef­fect. But one class of RNA has most­ly stumped re­searchers — un­til now.

Flamin­go Ther­a­peu­tics of­fi­cial­ly de­buted Thurs­day with three clin­i­cal and one pre­clin­i­cal can­cer drugs hand­ed off from an­ti­sense gu­ru Io­n­is, and an in­trigu­ing if un­proven dis­cov­ery en­gine gun­ning for mys­te­ri­ous long non-cod­ing RNA tar­gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.